LY3527026
Phase 2
Eli LillyLY3527026 is one of 99 therapeutic programs targeting Atopic Dermatitis. It is currently in Phase 2.
3
Indications
0
Total Trials
0
Active Trials
98
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Skyrizi
AbbViePhase 3
Eucrisa
AAnacor
Phase 3
Tagamet
DDT MedTech, LLC
Phase 3
SHR-1819
Guangdong Hengrui Pharmaceutical Co., LtdPhase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
OPA-15406
OtsukaPhase 3
Product 0405
FFougera Pharmaceuticals Inc.
Phase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Adtralza
LEO PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for LY3527026. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company